Vertex Pharmaceuticals Inc VRTX

The Motley Fool 14 nov

Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.

The Motley Fool 13 nov

The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.

Zacks Investment Research 11 nov

Vertex Pharmaceuticals has been heavily searched on Zacks.com and has outperformed the broader market with a +12.9% return over the past month. However, the company faces headwinds with declining earnings estimates and a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the market. The stock is trading at a premium valuation (Grade D) relative to peers, with mixed earnings surprise history.

GlobeNewswire Inc. 11 nov

Vertex released its 2026 CompOps Index showing that enterprises with indirect tax as a standing board item are four times less likely to have errors identified externally and nearly twice as likely to respond to tax-authority notices within five business days. Only 16% of enterprises currently have indirect tax as a standing board item, while 43% only discuss it when problems arise. The study also found that enterprises with board-level tax discussions are more likely to deploy AI autonomously in tax workflows (54% vs. 21%) and maintain better regulatory compliance.

The Motley Fool 8 nov

The article recommends five biotech stocks as attractive long-term investments: Vertex Pharmaceuticals for its cystic fibrosis dominance and kidney disease pipeline; Amgen for its diversified portfolio with 17 products showing double-digit growth; Gilead Sciences for its strong HIV drug portfolio and expanding oncology presence; Exelixis for its successful oncology focus with Cabometyx; and Regeneron Pharmaceuticals for its recovery driven by new Eylea formulation and Dupixent growth.